Should You Hold Intellia Therapeutics Inc (NTLA) in Biotechnology Industry?

A rating of 91 puts Intellia Therapeutics Inc (NTLA) near the top of the Biotechnology industry according to InvestorsObserver. Intellia Therapeutics Inc's score of 91 means it scores higher than 91% of stocks in the industry. Intellia Therapeutics Inc also received an overall rating of 65, putting it above 65% of all stocks. Biotechnology is ranked 74 out of the 148 industries.

NTLA has an Overall Score of 65. Find out what this means to you and get the rest of the rankings on NTLA!

See Full NTLA Report

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Intellia Therapeutics Inc Stock Today?

Intellia Therapeutics Inc (NTLA) stock is flat 0% while the S&P 500 is lower by -1.93% as of 1:56 PM on Friday, Apr 22. NTLA is flat $0.00 from the previous closing price of $50.51 on volume of 294,192 shares. Over the past year the S&P 500 is higher by 4.21% while NTLA is lower by -32.29%. NTLA lost -$3.78 per share the over the last 12 months. Click Here to get the full Stock Report for Intellia Therapeutics Inc stock.